Molecular Formula | C19H15N3O2 |
Molar Mass | 317.34 |
Density | 1.37±0.1 g/cm3(Predicted) |
Boling Point | 627.4±55.0 °C(Predicted) |
Solubility | DMSO: ≥ 32 mg/mL |
pKa | 7.79±0.60(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
In vitro study | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC 50 of 1.8 nM; the IC 50 of CP21R7 against PKCα is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.151 ml | 15.756 ml | 31.512 ml |
5 mM | 0.63 ml | 3.151 ml | 6.302 ml |
10 mM | 0.315 ml | 1.576 ml | 3.151 ml |
5 mM | 0.063 ml | 0.315 ml | 0.63 ml |
biological activity | CP21R7 (CP21) is a potent and selective inhibitor of GSK-3β, it can effectively activate the canonical Wnt signaling pathway. |
Target | TargetValue GSK-3β (Cell-free assay) |
Target | Value |
in vitro study | CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC 50 of 1.8 nM; the IC 50 of CP21R7 against PKC α is 1900 nM. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm. |